ANI And Eton Launch CGT Carbaglu Rival
ANI Also Gets FDA Nod For Rifabutin Rival To Mycobutin
ANI Pharmaceuticals and Eton Pharmaceuticals have announced the launch of their Carbaglu rival, with the companies having been granted a Competitive Generic Therapy designation by the FDA, along with 180 days of related exclusivity. ANI has also announced receiving FDA approval for its abbreviated new drug application for Mycobutin rival, Rifabutin capsules for 150mg dose.
